Oncolytics Biotech Inc ONCY

Big Pharma making multi-billion $$ biotech acquisitions

[Noteable]

April 24, 2023 - " Our Take: [The] latest [Merck and GSK] acquisitions follow a trend in which large pharma companies are scooping up smaller firms that have successfully developed drug candidates through the initial clinical stages. While they may pay a hefty premium, they’re able to avoid the costs associated with discovery and early failed trials. 

Buying smaller companies with attractive drug candidates — especially in the biotech sector, which has struggled mightily in the last few years — also gives Big Pharma companies a relatively smoother and less expensive way to expand into therapeutic areas beyond those already in their pipelines."

https://www.darwinresearch.com/our-take-biotech-sector-gets-a-boost-with-two-big-pharma-companies-announcing-multibillion-dollar-acquisitions/

[Noteable]

Factors driving the uptick in Big Pharma M&A activities include an upcoming patent cliff from 2026 to 2029, pricing pressure and 13 years of FDA exclusivity for novel "biologicals" derived from the U.S. Inflation Reduction Act, according to Moody’s. A late 2022 Deloitte survey, found further reason for optimism in M&A deals, owing to their potential to drive “new growth

[Noteable]

The recent M&A developments in the pharma and biotech sector are triggering revived interest in late-stage biotech companies like ONCY, which is proving pelareorep is prepared for 2 Phase 3 ready registration studies and the newly IRA announced FDA opportunity for an accelerated approval.

[Noteable]

Let's stick to these facts and not some "alternative facts" that those myth-makers would like to spin.

[Noteable]

Big Pharma's M&A "sweet spot" still remains between US$5 and US$15 Billion for bolt-on assets.

[fox7mf]

Of course we'd all love a buyout in the double digit billions, that goes without saying. But, I would not be apoplectic to hear a LOI for $3b to $4b was signed by the BOD. What about you Noteable? I agree with your valuation of Oncy, but if we get  substantially less, but still decent, would you be angered?

[Noteable]

Big Pharma acquisitions signalling accelerated pace of M&A.- (Fiercepharma) "Moody’s Investor Services thinks these are just the start, with M&A activity expected to remain high over the next year to 18 months. Pharmas are trying to restock their pipelines due to approaching patent cliffs and long-term pricing pressure, Moody’s wrote in a Monday (April 18th) sector commentary

[Noteable]

“Pharma’s topline is estimated to take a hit in the range of $258 billion over the next three years” due to expiring patents, said Arda Ural, EY Industry Markets Leader of Health Sciences and Wellness, and Big Pharma companies seem to have set money aside in preparation. “At the beginning of 2023, Pharma held a record $1.4 trillion in its collective balance sheet to deploy toward